Ionis Pharmaceuticals Approaches Its Earnings Call With Pipeline Momentum and Profitability Questions in Balance

Ionis Pharmaceuticals reports first-quarter 2026 earnings tomorrow before market open, with analysts expecting a loss of $0.89 per share—a modest improvement from the prior quarter's $1.41 loss but still reflecting the biotech's ongoing investment phase. The central question is whether the company can demonstrate progress in its RNA-targeted therapeutics pipeline while managing the sharp earnings deterioration analysts are forecasting for the full year, with consensus calling for a 72% decline in EPS compared to 2025.

Part 1: Earnings Preview

Ionis Pharmaceuticals is a biotechnology company focused on discovering and developing RNA-targeted therapies using proprietary antisense oligonucleotide (ASO) technology to modulate gene expression across neurological, cardiovascular, metabolic, and rare genetic disorders. Since its 1989 founding, the company has built a pipeline spanning multiple therapeutic areas, with revenue generated through both product sales and partnership agreements.

Ionis reports Q1 2026 earnings on April 29 before market open, with analysts expecting a loss of $0.89 per share on revenue of $202.89 million. The company most recently reported Q4 2025 earnings of -$1.41 per share, missing estimates by $0.18. Compared to the same quarter last year (Q1 2025), when Ionis reported a loss of $0.93 per share, the current consensus represents a 4.30% improvement year-over-year—a modest positive in an otherwise challenging earnings trajectory.

Three key themes define this earnings story:

Pipeline Progress and Regulatory Milestones: Investors will scrutinize updates on Ionis' clinical programs and any regulatory developments that could validate the company's ASO platform. With the stock trading below most near-term moving averages and analyst price targets implying 42% upside, tangible pipeline advancement is critical to rebuilding confidence.

Revenue Volatility and Partnership Dynamics: Recent quarters have shown dramatic revenue swings—Q2 2025 delivered $452 million (well above the $271 million estimate), while Q1 2025 came in at just $132 million (below the $144 million consensus). This volatility reflects the lumpy nature of partnership payments and milestone revenues, making quarterly predictability a persistent challenge.

Full-Year Outlook Deterioration: Analysts have slashed full-year 2026 EPS estimates to -$4.10 from a prior -$2.38, representing a 72% decline from 2025 levels. Management's guidance and commentary on operating expenses, R&D spending, and the path to profitability will be crucial in determining whether this pessimism is warranted or overdone.

Analyst commentary ahead of the release reflects cautious optimism tempered by near-term headwinds. Wells Fargo raised its price target from $82 to $100 with an "overweight" rating, while Leerink Partners increased its target from $102 to $104, maintaining an "outperform" stance. Canaccord Genuity initiated coverage with a "buy" rating and $110 target. However, the consensus remains that Ionis faces a challenging 2026 as it invests heavily in pipeline development while managing negative cash flow from operations.

Part 2: Historical Earnings Performance

Ionis has demonstrated a mixed but generally positive track record of beating analyst estimates, exceeding consensus in six of the last eight quarters. The company's surprise pattern shows meaningful variability: Q2 2025 delivered an extraordinary 736% beat when reporting $0.70 versus an expected loss of $0.11, while Q4 2025 represented a rare miss with -$1.41 versus -$1.31 estimated (a -7.63% surprise). The three quarters preceding that miss all beat expectations—Q3 2025 by 35%, Q1 2025 by 20%, and Q4 2024 by 41%.

The magnitude of surprises has been substantial, particularly on the upside. Beyond the Q2 2025 outlier, Ionis posted double-digit percentage beats in four of the last seven quarters, suggesting the company has either been conservative in guiding analysts or has experienced better-than-expected partnership milestone payments. The lone negative surprise in Q4 2025 was relatively modest at -7.63%, indicating that when Ionis does miss, the shortfall tends to be contained.

Looking at the trend, Ionis appears to have entered a more volatile earnings phase in 2025, with results swinging from significant beats to a modest miss. This pattern aligns with the lumpy revenue recognition inherent in biotech partnership agreements and milestone payments, making quarter-to-quarter predictability challenging despite the company's overall tendency to exceed lowered expectations.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Ionis typically reports earnings before market open, meaning Day 0 captures the market's immediate reaction in the first full trading session, while Day +1 reflects follow-through momentum.

Historical price behavior shows Ionis averaging a 2.90% absolute move on earnings day (Day 0) with an intraday range of 6.29%, followed by a 2.27% move on Day +1 with a 4.72% range. The most recent earnings on February 25, 2026, produced a 5.29% decline on Day 0—the largest single-day drop in the past year—followed by minimal Day +1 movement of just 0.41%. This contrasts sharply with the July 2025 report, which saw a 4.56% Day 0 gain but gave back ground with a 0.90% decline the following session.

The data reveals a pattern of initial volatility that often moderates by Day +1, though directional consistency varies. October 2025 showed a muted 2.30% Day 0 decline followed by a stronger 3.19% Day +1 rally, while August 2024 demonstrated the opposite—a 3.76% Day 0 gain reversed into a 4.27% Day +1 loss. The widest intraday ranges occurred in February 2025 (11.64% on Day 0) and April 2025 (7.13% on Day +1), suggesting that market reactions can be particularly volatile when results significantly diverge from expectations. Investors should anticipate meaningful price movement tomorrow, with historical patterns suggesting the initial reaction may not fully capture the ultimate directional move.

Part 2.2: Options Market Expected Move

The options market is pricing a 6.31% expected move through the May 15 expiration (17 days out), which sits at the upper end of historical Day 0 ranges (6.29% average) but below the most volatile recent reactions. This implies options traders are anticipating above-average volatility for this release, consistent with the heightened uncertainty around full-year guidance and the sharp deterioration in analyst EPS estimates for 2026.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Ionis with an average rating of 4.41 out of 5.0 (between Buy and Strong Buy), reflecting strong conviction despite near-term earnings headwinds. The consensus breaks down to 14 Strong Buys, 3 Moderate Buys, 5 Holds, and zero Sell ratings among 22 analysts covering the stock. This represents an improved sentiment trend from one month ago, when the firm had 13 Strong Buys and 2 Moderate Buys, indicating growing analyst confidence heading into the earnings release.

The average price target of $101.95 implies 42% upside from the current price of $71.78, with a wide range spanning from a low of $71.00 to a high of $130.00. This substantial upside potential reflects analyst belief that the market is undervaluing Ionis' pipeline and partnership opportunities, even as the company navigates a challenging 2026. The target range's breadth—from essentially flat to 81% upside—underscores the divergent views on execution risk and the timeline to profitability.

Recent analyst actions support the bullish tilt: Wells Fargo's upgrade to $100, Leerink Partners' increase to $104, and Canaccord Genuity's new $110 target all came in the first quarter of 2026, suggesting fresh conviction following the company's strategic updates. Royal Bank of Canada reiterated its "outperform" rating in late February, while Stifel Nicolaus raised its target from $73 to $77 with a "hold" rating—one of the few cautious voices in an otherwise optimistic analyst community. The improving sentiment trend, combined with the concentration of Strong Buy ratings, indicates analysts view current levels as an attractive entry point despite the near-term earnings deterioration.

Part 4: Technical Picture

Ionis enters earnings with a 40% Sell signal from the Barchart Technical Opinion, representing a significant deterioration from just one week ago (8% Sell) and one month ago (8% Sell). This sharp weakening in technical momentum over the past week suggests growing selling pressure as the stock has declined into the earnings release.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, with the stock losing ground heading into the report
• Medium-term (50% Sell): Matching sell pressure in the intermediate timeframe suggests the weakness is not just a short-term phenomenon but reflects broader trend deterioration
• Long-term (Hold): Neutral reading in the longer-term view provides some stability, indicating the fundamental trend has not completely broken down despite recent weakness

Trend Characteristics: The combination of Minimum strength and Average direction signals a weak, directionless trend environment heading into earnings—a setup that typically amplifies volatility as the market lacks conviction in either direction.

The stock is trading at $71.78, positioned below the 5-day ($73.24), 10-day ($74.36), 20-day ($74.76), 50-day ($75.74), and 100-day ($78.31) moving averages, but above the 200-day moving average ($69.21). This configuration—underwater across all short- and intermediate-term timeframes while maintaining support above the long-term trend—paints a picture of a stock in a corrective phase that has not yet broken its broader uptrend.

The technical setup is cautionary heading into earnings, with the stock failing to hold support at multiple moving average levels and momentum indicators flashing sell signals across short- and medium-term timeframes. The 200-day moving average at $69.21 represents critical support just 3.7% below current levels—a break below that threshold on disappointing results could trigger further technical selling. Conversely, a strong earnings beat would need to reclaim the 50-day moving average at $75.74 to signal a meaningful reversal of the recent downtrend. The weak technical positioning amplifies downside risk if results or guidance disappoint, while also creating potential for an outsized rally if the company surprises positively and catalyzes short covering.